Acute heart failure following the initiation of cabozantinib, a multikinase inhibitor: A case report.

ABSTRACT: Cabozantinib is a multikinase inhibitor that exerts anticancer activity against malignancies such as renal tumors and leukemia. Although other agents that belong to the same category can cause cardiotoxicity, there is a paucity of information on the safety profile of cabozantinib. Herein, we present the case of a 62-year-old woman who developed acute heart failure (HF) following the initiation of cabozantinib for a metastatic renal tumor. She had no history of cardiovascular disease. Echocardiography prior to chemotherapy revealed normal cardiac function. However, she developed sudden onset of dyspnea 23 days following cabozantinib initiation. The chest X-ray showed newly developed congestion and cardiomegaly, and echocardiography revealed severe impairment of systolic and diastolic functi

SUBMITTER: Ishiguchi H 

PROVIDER: S-EPMC9449766 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature